Keywords: Eisai, Halaven, Advanced beast cancer, European Commission

Eisai’s Halaven cleared in Europe for advanced breast cancer

Article | 25 March 2011

Print This

Japanese drug major Eisai (TYO: 4532) has received approval from the European Commission for Halaven (eribulin) for the treatment of patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in